Phase 3 Clinical Trials With Primary Completion Dates in May 2022

This is a list of Phase 3 trials with primary completion dates in May 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ARQTArcutis Biotherapeutics, Inc.2022-05-01Phase 3NCT04973228Trial of PDE4 Inhibition With Roflumilast for the Management of Seborrheic Dermatitis (STRATUM)
CNCEConcert Pharmaceuticals, Inc.2022-05-01Phase 3NCT04518995A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)
GKOSGlaukos Corporation2022-05-01Phase 3NCT03868124Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
JAZZJazz Pharmaceuticals plc2022-05-01Phase 3NCT04657666Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
PTCTPTC Therapeutics, Inc.2022-05-01Phase 3NCT03179631Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
SELBSelecta Biosciences, Inc.2022-05-01Phase 3NCT04513366A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
VNDAVanda Pharmaceuticals Inc.2022-05-01Phase 3NCT04819776Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder
VTGNVistaGen Therapeutics, Inc.2022-05-01Phase 3NCT04754802PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge